Danish biopharmaceutical company H. Lundbeck A/S (CPH:HLUN-A) announced on Wednesday that it has received Fast Track designation from the US Food and Drug Administration (FDA) for amlenetug, an investigational treatment for multiple system atrophy (MSA).
This designation is based on results from the AMULET phase II trial, presented in March 2024 at the International Conference on Alzheimer's and Parkinson's Diseases.
Lundbeck has recently initiated MASCOT, a phase III trial to evaluate amlenetug's efficacy and safety in MSA. Fast Track designation enables the company to engage in more frequent interactions with the FDA and benefit from rolling reviews to expedite the drug's development.
Amlenetug has also received Orphan Drug Designation from the FDA (April 2024) and the European Medicines Agency (May 2021), and the SAKIGAKE designation from Japan's Ministry of Health, Labor and Welfare (March 2023).
Developed under a joint research and licensing agreement between Lundbeck and Danish biotechnology company Genmab A/S (CPH:GMAB), amlenetug is a human monoclonal antibody designed to bind to extracellular α-synuclein, potentially inhibiting its aggregation.
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
Fusion Antibodies secures USD460,000 in follow-on contracts with US biotechnology client
INOVIO to begin rolling submission of BLA for INO-3107
ZYUS Life Sciences begins Phase 2a cancer pain trial with first patient enrolled
Curasight secures approval for phase 1 trial of uTREAT in glioblastoma patients
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
Calluna Pharma begins Phase 2 study of CAL101 in idiopathic pulmonary fibrosis
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
BioArctic and Novartis sign an option, collaboration and license agreement
Curasight's uTREAT clinical trial application approved in Europe
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Lighthouse Pharmaceuticals announces receipt of USD49.2m grant from NIA for LHP588 study
Innovent Biologics receives approval over squamous cell lung cancer study
Cambrex announces expansion of peptide manufacturing capabilities in Waltham, Massachusetts
Tyra Biosciences doses first child in dabogratinib Phase 2 achondroplasia clinical study